Andrew Berens
Stock Analyst at Leerink Partners
(2.33)
# 2,631
Out of 5,132 analysts
98
Total ratings
47.56%
Success rate
-1.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $3.72 | +115.05% | 1 | Jan 23, 2026 | |
| COGT Cogent Biosciences | Maintains: Outperform | $14 → $15 | $36.53 | -58.94% | 6 | Jun 13, 2022 | |
| GLTO Galecto | Initiates: Outperform | $46 | $29.12 | +57.97% | 1 | Jan 7, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $27.96 | +43.06% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $100.89 | +47.69% | 3 | Nov 17, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $4.93 | +204.26% | 1 | Oct 31, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $11.25 | +122.22% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $104.51 | -42.59% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $11.65 | -22.75% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $6.28 | -4.46% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $803.17 | -5.13% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.45 | +1,246.94% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $22.60 | +10.62% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $154.98 | -38.06% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $101.10 | -22.85% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $15.60 | +79.49% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $205.55 | -61.57% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $2.39 | +1,029.71% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $11.59 | +115.70% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.57 | +618.13% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $1.89 | +3,444.97% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $17.92 | +11.61% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $12.90 | +93.80% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $8.88 | -9.91% | 7 | Jul 14, 2017 |
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $3.72
Upside: +115.05%
Cogent Biosciences
Jun 13, 2022
Maintains: Outperform
Price Target: $14 → $15
Current: $36.53
Upside: -58.94%
Galecto
Jan 7, 2026
Initiates: Outperform
Price Target: $46
Current: $29.12
Upside: +57.97%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $27.96
Upside: +43.06%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $100.89
Upside: +47.69%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $4.93
Upside: +204.26%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $11.25
Upside: +122.22%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $104.51
Upside: -42.59%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $11.65
Upside: -22.75%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $6.28
Upside: -4.46%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $803.17
Upside: -5.13%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.45
Upside: +1,246.94%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $22.60
Upside: +10.62%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $154.98
Upside: -38.06%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $101.10
Upside: -22.85%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $15.60
Upside: +79.49%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $205.55
Upside: -61.57%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $2.39
Upside: +1,029.71%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $11.59
Upside: +115.70%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.57
Upside: +618.13%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.89
Upside: +3,444.97%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $17.92
Upside: +11.61%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $12.90
Upside: +93.80%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $8.88
Upside: -9.91%